

@article{middleton_pembrolizumab_2020,
	title = {Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 ({PePS2}): a single arm, phase 2 trial},
	volume = {0},
	issn = {2213-2600, 2213-2619},
	shorttitle = {Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 ({PePS2})},
	url = {https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30033-3/abstract},
	doi = {10.1016/S2213-2600(20)30033-3},
	language = {English},
	number = {0},
	urldate = {2020-03-21},
	journal = {The Lancet Respiratory Medicine},
	author = {Middleton, Gary and Brock, Kristian and Savage, Joshua and Mant, Rhys and Summers, Yvonne and Connibear, John and Shah, Riyaz and Ottensmeier, Christian and Shaw, Paul and Lee, Siow-Ming and Popat, Sanjay and Barrie, Colin and Barone, Gloria and Billingham, Lucinda},
	month = mar,
	year = {2020},
	note = {Publisher: Elsevier}
}


@article{Herbst2016,
	title = {Pembrolizumab versus docetaxel for previously treated, {PD}-{L1}-positive, advanced non-small-cell lung cancer ({KEYNOTE}-010): {A} randomised controlled trial},
	volume = {387},
	issn = {1474547X},
	doi = {10.1016/S0140-6736(15)01281-7},
	number = {10027},
	journal = {The Lancet},
	author = {Herbst, Roy S. and Baas, Paul and Kim, Dong Wan and Felip, Enriqueta and Pérez-Gracia, José L. and Han, Ji Youn and Molina, Julian and Kim, Joo Hang and Arvis, Catherine Dubos and Ahn, Myung Ju and Majem, Margarita and Fidler, Mary J. and De Castro, Gilberto and Garrido, Marcelo and Lubiniecki, Gregory M. and Shentu, Yue and Im, Ellie and Dolled-Filhart, Marisa and Garon, Edward B.},
	year = {2016},
	pmid = {26712084},
	note = {ISBN: 0140-6736},
	keywords = {NSCLC, PD1, pembrolizumab, Pembrolizumab},
	pages = {1540--1550}
}


@article{Garon2015,
	title = {Pembrolizumab for the treatment of non-small-cell lung cancer.},
	volume = {372},
	issn = {1533-4406},
	url = {http://www.ncbi.nlm.nih.gov/pubmed/25891174},
	doi = {10.1056/NEJMoa1501824},
	number = {21},
	journal = {The New England journal of medicine},
	author = {Garon, Edward B and Rizvi, Naiyer a and Hui, Rina and Leighl, Natasha and Balmanoukian, Ani S and Eder, Joseph Paul and Patnaik, Amita and Aggarwal, Charu and Gubens, Matthew and Horn, Leora and Carcereny, Enric and Ahn, Myung-ju and Felip, Enriqueta and Lee, Jong-seok and Hellmann, Matthew D and Hamid, Omid and Goldman, Jonathan W and Soria, Jean-charles and Dolled-Filhart, Marisa and Rutledge, Ruth Z and Zhang, Jin and Lunceford, Jared K and Rangwala, Reshma and Lubiniecki, Gregory M and Roach, Charlotte and Emancipator, Kenneth and Gandhi, Leena and {KEYNOTE-001 Investigators}},
	year = {2015},
	pmid = {25891174},
	note = {ISBN: 1533-4406 (Electronic) 0028-4793 (Linking)},
	keywords = {NSCLC, PD1, pembrolizumab, Pembrolizumab},
	pages = {2018--28}
}


@inproceedings{brock_phase_2019,
	address = {Cham},
	series = {Springer {Proceedings} in {Mathematics} \& {Statistics}},
	title = {A {Phase} {II} {Clinical} {Trial} {Design} for {Associated} {Co}-primary {Efficacy} and {Toxicity} {Outcomes} with {Baseline} {Covariates}},
	isbn = {978-3-030-30611-3},
	doi = {10.1007/978-3-030-30611-3_13},
	language = {en},
	booktitle = {Bayesian {Statistics} and {New} {Generations}},
	publisher = {Springer International Publishing},
	author = {Brock, Kristian and Billingham, Lucinda and Yap, Christina and Middleton, Gary},
	editor = {Argiento, Raffaele and Durante, Daniele and Wade, Sara},
	year = {2019},
	keywords = {MyPubs, Covariate, Efficacy, Phase ii, Toxicity, Trial},
	pages = {125--133}
}


@article{alessi_immunotherapy_2020,
	title = {Immunotherapy in lung cancer: effective for patients with poor performance status?},
	issn = {22132600},
	shorttitle = {Immunotherapy in lung cancer},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S2213260020301077},
	doi = {10.1016/S2213-2600(20)30107-7},
	language = {en},
	urldate = {2020-03-26},
	journal = {The Lancet Respiratory Medicine},
	author = {Alessi, Joao V and Awad, Mark M},
	month = mar,
	year = {2020},
	pages = {S2213260020301077}
}

